For in vitro diagnostic use. Others Elecsys Anti-HBs II IVD Elecsys® Anti-HBs II CPS_000441 08498598190 Anti-HBs G2 Elecsys cobas e 100 V2 Elecsys Anti-HBs II 07613336160350 Reagents, kits 100 tests cobas e 411/601/602 true 08498610160 Anti-HBs G2 Elecsys E2G 300 V2 Anti-HBs G2 Elecsys E2G 300 V2 07613336230367 Reagents, kits 300 tests cobas e 402 undefined 08498601190 Anti-HBs G2 Elecsys cobas e 200 V2 Elecsys Anti-HBs II 07613336160374 Reagents, kits 200 tests cobas e 411/601/602 true 05894816190 Anti-HBs G2 Elecsys cobas e 100 Elecsys Anti-HBs II 04015630928538 Reagents, kits 100 tests cobas e 411/601/602 true 08498610519 Anti-HBs G2 Elecsys E2G 300 V2 Elecsys Anti-HBs II Reagents, kits 300 tests cobas e 402/801 08498610190 Anti-HBs G2 Elecsys E2G 300 V2 Elecsys Anti-HBs II 07613336160381 Reagents, kits 300 tests cobas e 402/801 true 08498598160 Anti-HBs G2 Elecsys cobas e 100 V2 Anti-HBs G2 Elecsys cobas e 100 V2 07613336160367 Reagents, kits 100 tests cobas e 411/601/602 true 08498610509 Anti-HBs G2 Elecsys E2G 300 V2 Elecsys Anti-HBs II Reagents, kits 300 tests cobas e 402/801 08498598500 Elecsys Anti-HBs II en 3 FF000000049F470E FF000000037BD70E 08498598190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of human antibodies to the hepatitis B surface antigen (HBsAg) in human serum and plasma.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08498610501 Elecsys Anti-HBs II en 1 FF0000000713890E FF0000000713880E 08498610160 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of total antibodies to the hepatitis B surface antigen (HBsAg) in human adult, pregnant women, and pediatric (ages 2 to 21 years) serum and plasma (K2‑EDTA and K3‑EDTA). Assay results may be used as an aid in the determination of susceptibility to hepatitis B virus (HBV) infection for individuals prior to or following HBV vaccination; or where vaccination status is unknown. Assay results may be used with other HBV serological markers for the laboratory diagnosis of HBV disease associated with HBV infection. A reactive assay result will allow a differential diagnosis in individuals displaying signs and symptoms of hepatitis in whom etiology is unknown. The detection of anti‑HBs is indicative of laboratory diagnosis of seroconversion from HBV infection or from vaccination.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08498601500 Elecsys Anti-HBs II en 3 FF000000049F8C0E FF000000037BD90E 08498601190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of human antibodies to the hepatitis B surface antigen (HBsAg) in human serum and plasma.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 05894816500 Elecsys Anti-HBs II en 3 FF000000049F920E FF000000012ED80E 05894816190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of human antibodies to the hepatitis B surface antigen (HBsAg) in human serum and plasma.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 08498610500 Elecsys Anti-HBs II en 2 FF0000000493EE0E FF0000000375900E 08498610190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of human antibodies to the hepatitis B surface antigen (HBsAg) in human serum and plasma.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08498610500 Elecsys Anti-HBs II en 1 FF0000000378200E FF0000000378200E 08498610190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of human antibodies to the hepatitis B surface antigen (HBsAg) in human serum and plasma.The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 801 immunoassay analyzer. en 08498598501 Elecsys Anti-HBs II en 1 FF0000000714BB0E FF0000000713800E 08498598160 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of total antibodies to the hepatitis B surface antigen (HBsAg) in human adult, pregnant women, and pediatric (ages 2 to 21 years) serum and plasma (K2‑EDTA and K3‑EDTA). Assay results may be used as an aid in the determination of susceptibility to hepatitis B virus (HBV) infection for individuals prior to or following HBV vaccination; or where vaccination status is unknown.Assay results may be used with other HBV serological markers for the laboratory diagnosis of HBV disease associated with HBV infection. A reactive assay result will allow a differential diagnosis in individuals displaying signs and symptoms of hepatitis in whom etiology is unknown. The detection of anti-HBs is indicative of laboratory diagnosis of seroconversion from hepatitis B virus (HBV) infection or from vaccination.The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 601 and 602 immunoassay analyzers. en